Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
ABBEYCREST
(SEA:
ACR
)
0.0145
GBP
UNCHANGED
Last Price
/ Updated:
9:33 AM EST, Jan 25, 2012
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Blog posts about ABBEYCREST
Your next TV set may show you advertising spots you actually like
December 14, 2012
Media data specialist Gracenote wants to show you ads that matter to what you watch and who you are. To do so, the company is looking to embed video recognition and ad swapping technology right into...
Read More
category
acr
,
Stephen White
,
video recognition technology
from
GigaOM
Shazam exec: The second screen is where it’s at
September 17, 2012
Shazam's mobile app is now able to recognize almost any TV show on more than 160 U.S. TV channels - but it isn't looking to take those smarts into the set-top box space any time soon. One reason:...
Read More
category
acr
,
second screen
from
GigaOM
Flingo’s SyncApps let you tweet directly from your TV
January 09, 2012
Flingo is making an appearance at the Consumer Electronics Show this year, and it will be showing off a little bit of technology that will let viewers share what they're watching on social networks...
Read More
category
Twitter
,
social media
,
facebook/inc
, and 3 more.
from
GigaOM
Testosterone Drug Approved
November 29, 2010
Acrux Limited (ASX:ACR) and Eli Lilly Company (LLY) announced that the FDA has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone...
Read More
category
Latest
,
WallStreet
,
Business
from
Wall Street Pit
(JNJ) Johnson and Johnson Sees Encouraging Phase III Data
November 24, 2009
Johnson and Johnson (JNJ) recently presented long-term data from two phase III clinical trials of Simponi (golimumab), carried out on rheumatoid arthritis (RA) patients. It was observed that patients...
Read More
category
JNJ
,
Healthcare
,
Johnson & Johnson
, and 3 more.
from
Stock Blog Hub
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here